Ascendis Pharma A/S
At today's price, Ascendis Pharma A/S (ASND) is priced for today's economics sustained for ~10.6 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Ascendis has turned its TransCon drug-delivery platform into three approved endocrine rare-disease products: YORVIPATH for hypoparathyroidism, SKYTROFA for growth hormone deficiency, and, as of February 2026, YUVIWEL (navepegritide) for achondroplasia [Source: Ascendis FDA approval release, February 2026]. • The company just crossed into operating profitability: first-quarter 2026 revenue reached €247 million, up from €101 million a year earlier and driven mainly by YORVIPATH, for a €25 millio
Is ASND overvalued? See what's priced in →
269 institutional managers reported holding ASND in 13F filings for the quarter ended 2026-03-31. 31 opened new positions that quarter. Held by FMR (Fidelity), Artisan Partners, Franklin Resources, among others. On the short side, 2.0M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (3.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ASND's share count grew 12.8% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at ASND over the trailing three years: 2026: 4 buys totaling $284k. 12 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
Last analyzed: July 19, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.